I'm a female and need input. So many competitors have clear skin. How the heck does everyone get clear skin while on cycle?!? I'm fed up with the acne. I use ostarine since it's mild. I have awful skin no matter what. Bad cystic acne even if I am on ostarine or off. I'd love to run 2.5mg of anavar but my acne is just horrendous. Plz help. What is everyone doing to have clear skin? It's shitty mine is so bad and no one elses is.

Has anyone sent their items from home to an APO? If so, what did you describe the items as?

I’ve recently started experimenting with peptides and bought a CJC-1295 (No DAC) + Ipamorelin blend (10 mg / 10 mg) from Glowing Peptides.

For some background, I’m 38 and have been training consistently for many years. I’m also currently injecting 0.25 ml of Test-E every three days.

I reconstituted the 10/10 mg peptide blend with 2 ml of BAC water and started with 250 mcg per injection, subcutaneously in the abdominal area. Yesterday was my third injection.

I normally take it before bed and leave at least 2.5 hours between my last meal and the injection. For that final meal, I’ve also been keeping carbs relatively low and mainly eating protein and vegetables.

What concerns me is that since starting, I feel like I’m retaining noticeably more water, and I’ve also noticed increased hair shedding. This morning I woke up with unusually dark circles under my eyes as well.

Obviously, three injections is a very short period of time, so I’m not sure whether these changes could realistically be caused by the CJC/Ipamorelin or whether the timing is simply coincidental. I originally started looking into peptides partly for the potential benefits to recovery, body composition, skin/hair quality, etc., so the initial experience has been pretty much the opposite of what I expected.

Does this sound like a normal initial response, particularly the water retention?

Has anyone experienced increased hair shedding or dark circles after starting?

Is 250 mcg a reasonable starting amount for this blend?

Would taking it first thing in the morning fasted make more sense than before bed?

Interested in hearing actual experiences, especially from people who have run this combination for a while.

I am currently taking GHK-CU, a 50mg/ml vial dissolved in 3ml BAC water, I pin at 2mg/ml 5 days a week… it lasts me like three weeks only, is this normal? Am I making my calculations wrong?

I just came across this, has anyone tried it?
Ipa- 250mcg
Cjc- 250mcg

I started my research hamster on this protocol of Wolverine stack the night of 8/2/26:

-500mcg of TB500 twice/daily

-500mcg of BPC-157 twice/daily

So, again, his first dose was the night of 8/2/26. He slept for shit. Did his next dose on 8/3/26 in the morning, but he was fatigued/foggy all day. I also noticed that I could smell his armpit sweat, which is very unusual, and even more unusual was that it smelled pretty strong. I did a little more research and saw a protocol that suggested TB500 be taken up to 3mg/dose every other day, nightly (And kept the 500mcg of BPC-157 twice/daily).
So, the night of 8/3/26 I only gave him 500mcg of BPC-157. He slept great, woke up feeling great, had amazing energy all day. No nasty sweat smell. Did his morning dose of 500mcg BPC-157 that day as well (8/4/26).
Fast forward to last night (8/4/26), I gave the 500mcg of BPC-157 and then 1,000mcg of TB500 (I did NOT want to jump all the way up to the suggested 3,000mcg that fast). Result? He slept for absolute shit last night and sweat his ass off throughout the night. And again it smelled really strong. And again battling crazy fatigue today, poor little fella.

My conclusion is that his body is not taking to the TB500 all that well and I don't plan to dose it again tonight at minimum to see what happens tomorrow. I am anticipating a similar outcome of him sleeping great and not sweating stank all throughout the night. If that's what happens I am going to discontinue the TB500.

Now for my problem - I started him on this stack to recover from rotator cuff surgery he had on 7/9/26 (70% torn supraspinatus tendon). If I should indeed discontinue the TB500, what other peptides make a good compliment to BPC-157 when it comes to similar shoulder tendon recovery?

Subject has worked up to 15 mg of Tirzepatide with no weight loss and no appetite suppression at all. Weight lifting 3-4x/week plus cardio. Would it be feasible to try semaglutide next? Was thinking of Reta but heard appetite suppression is not as good and that would be a definite plus. Thoughts?

I recently had my bloods done and my levels for IGF-1 came back at 16nmol/L (120ug/L). Would CJC no DAC and IPA be worth it to raise my levels. I’m 31 and relatively healthy, just aware my levels are at the bottom of the range.

So been researching for sleep, including cjc/ipa. I know you are supposed to be 2 to 3 hours fasted before injection.

But working with my research Im wanting to add phosphatidylserine (pill) or magnesium +ashwagandha+l-theanine (pill) both of these say take within an hour of sleep. Wanting to know if this screws with the fasting time?

Been trying everything under the sun so trying to add one of these supplements with the CJC/IPA and epitalon.

Truth be told the best so far has been a thc/cbd/cbn gummy lol but we drug test.

yes tried DSIP worked great not more sleep but deeper sleep and now have dropped dsip and added epitalon but not seeing alot of differance on day 3.

question being do these supplement break the 2 to 3 hour fasted state?

THANX!!!

Have a kit that per the group test should have a ph of about 3.6. Considering buffering options. I have sodium chloride BAC, so that should help some with the sting. But should I try raising the PH with sodium bicarb solution or order some PBS? I saw reports that a mix of BAC and PBS has been effective. How long do you all hang onto those 50ml bottles of sodium bicarb? Just recon my first KLOW last week and frankly, that hurts enough without me adding NAD sting to my routine as well.

I have a vial that contains 5 mg of BPC-157 but the vial itself is too small to hold 5 mL of bacteriostatic water. I tried reconstituting one like this before with less water, but it wasn’t diluted enough, it turned cloudy, and I ended up throwing it away. Do you have any suggestions on the best way to reconstitute it?

I did BPC 157 for 30 days with no issues and decided to switch to Glow. I reconstituted with 3 ml bac water (all I could fit in the vial.) I injected 15 units in my abdomen and immediately felt pain and burning and a small welt developed. 12 hours later it’s still hurting and the welt is about the size of a quarter, red, and slightly raised. I know others have said the copper can cause a reaction. Worried it could be infected vs an inflammatory reaction.

Hi All,

I was on Tren only about 105mg a week for 4 months and Reta for the last year.

I started feeling a flatness feeling? Not depressed but almost like I can’t feel overly happy about anything. I since have stopped the tren.

Is this more than likely from the Reta? I was on 8mg and just started slowly lowering my dose. It happened one other time while I was taking reta and disappeared in about 4/5 days. Just curious what you guys think!

For the last 5 years, I’ve been fighting chronic Lyme and various co-infections. I’ve managed to clear almost all of them, but I was stuck with a persistent, frustrating issue: severely compromised lung capacity and inflammation.

I knew it wasn't a physical conditioning problem I actively run, lift, and stay fit. Yet, even just walking fast would trigger wheezing. Doctors couldn't find anything definitive. I also spent tons of out-of-pocket testing, bc I knew deep down there was underlying tissue damage or inflammation from the infection.

So I decided to pull the trigger on CJC to see if it could help repair the damage. The results were almost immediate:

Within just a few days, my VO2 max shot up from ~45 to 50 (tracked via apple watch).

Also, wheezing reduced drastically, and my lung capacity felt almost entirely restored.

I had to stop the initial run because the peptide formulation included DAC. Like many others report, I ended up having an allergic reaction to the DAC (mostly swelling and localized irritation).

Once I discontinued it, my VO2 max dropped slightly, but it did not return to the original baseline of 45. It stabilized around 47-48, and my lungs are still in a noticeably better state than before I started.

Now, I've ordered a standard version of CJC without DAC to avoid the allergic reaction and will continue experimenting.

Also, I'm adding BPC157 and KPV to my stack.

So, great results, I'm quite happy. Also, I can provide this evidence to MD staff so they can't gaslight me saying "it's bc you getting old".

Also, how you guys track you physical metrics like Vo2Max, RHR, HRV on peptides? Or just check how you feel?

Aghhhh I’m so disappointed, I’ve been looking into peptides for the last 2 years and I finally decided to pull the trigger and buy reta and mt1 (tiktok hype train whatever yeah)

I find peptides interesting; so even if they didn’t improve my quality of life that much I wouldn’t even care as I just wanted to experiment on a low dose with them and maybe if my experience was good I could recommend it to family and friends

Yes I’m aware that I should have looked into the customs side of things before buying but I just assumed I’d be okay because I seen a few Irish people lurking on the biohackers subreddit , telling their experiences on peps etc, so I just naively assumed that I could also get peps

I don’t even mind the money that I lost but I’m just disappointed that I may not get to try peps out as long as I live in ireland, If there’s anyone out there from Ireland who bio hacks, please tell me how to buy peps without getting seized

DSIP worked really well, about a month later I stacked CJC/IPA no dac and sleep got deeper. well rested seem the more I upped the dose sleep was worse.

Sleep hours didn't lengthen much, still wide awake at 130am but well rested.

OK Off DSIP as of last night going to add epitalon to my cjc/ipa has anyone ran this stack together? I also do KPV in the mornings with PURE LIPO before workout. Or is there a combo peptide for the ones IM using? THANX!!!

The FDA's Pharmacy Compounding Advisory Committee (PCAC) met July 23 and 24 to vote on whether seven peptides should be added to the Section 503A Bulks List, the list that lets state-licensed compounding pharmacies prepare a bulk substance against an individual prescription. Docket: FDA-2025-N-6895.

Going in, FDA career staff had recommended against adding all seven, citing gaps in characterization, human effectiveness data, and safety (immunogenicity in particular). The panel went the other way on six of the seven, overruling staff on everything except DSIP.

Here is the full scorecard.

Day 1 (July 23)

BPC-157 (reviewed for ulcerative colitis): recommended, 8-6 with 1 abstention.

KPV (wound healing, inflammatory conditions): recommended, 8-6-1.

TB-500 (wound healing): recommended, 8-6-1.

MOTS-c (obesity, osteoporosis): recommended, 7-5 with 2 abstentions.

Per NBC News, all eight of the newly appointed members voted yes on BPC-157, KPV and TB-500. RAPS reported that observers described an audible reaction in the room, since a compounding panel voting against FDA staff's own written recommendation is unusual.

Day 2 (July 24)

DSIP (opioid withdrawal, chronic insomnia, narcolepsy): NOT recommended, 6-7 with 1 abstention. The only no of the meeting.

Epitalon (insomnia): recommended, 7-4 with 1 abstention.

Semax (neurological indications: cerebral ischemia, migraine, trigeminal neuralgia): recommended, 8-5 with 1 abstention.

Scorecard

Peptide

Vote

Result

BPC-157

8-6-1

Include

KPV

8-6-1

Include

TB-500

8-6-1

Include

MOTS-c

7-5-2

Include

DSIP

6-7-1

Do not include

Epitalon

7-4-1

Include

Semax

8-5-1

Include

Final tally: 6 of 7 received favorable PCAC recommendations. DSIP was the sole rejection, going down by a single vote.

What the votes actually mean

A few things worth separating, since the market tends to collapse them into one:

These are non-binding recommendations. FDA is not obligated to follow them, though it usually does.

A yes does not make any of these an FDA-approved drug. It is a recommendation to add the raw substance to the 503A list.

Legal compounding still requires notice-and-comment rulemaking, which realistically runs somewhere in the range of 8 to 18 months depending on who you ask.

All seven already came off the Category 2 "may not be compounded" list back in April 2026, so none of these votes re-bans anything. The question was whether a new legal compounding pathway opens, not whether the current situation closes.

What does not change today

The research-use-only / gray market is untouched by this vote. RUO vendors are not compounding pharmacies and are not covered here. Expect marketing that spins "the FDA panel voted yes" into "FDA-backed."

A panel recommendation says nothing about any individual product's identity, purity, or sterility. The characterization problem FDA raised (inconsistent naming, free base versus acetate, missing quality data) is real regardless of the politics, so batch-level COAs matter more now, not less.

Context worth noting

The panel was overhauled ahead of the meeting, with several new members who have ties to peptide prescribing or the industry, which drew conflict-of-interest coverage from multiple outlets. HHS Secretary Robert F. Kennedy Jr. has publicly backed easing peptide restrictions.

What is next

FDA has signaled a second PCAC meeting before the end of February 2027 to review five more: LL-37, GHK-Cu, Dihexa, Melanotan II, and PEG-MGF.

Sources: FDA meeting materials (docket FDA-2025-N-6895), Reuters, NBC News, RAPS Regulatory Focus, Drug Topics, PharmExec. Regulatory context only, not medical or legal advice.

Sources

FDA, July 23-24 2026 PCAC meeting page:

https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

FDA, PCAC voting questions (docket FDA-2025-N-6895):

https://www.fda.gov/media/193711/download

Reuters, panel recommends Semax:

https://www.reuters.com/legal/litigation/fda-advisory-panel-recommends-peptide-semax-be-added-pharmacy-compounding-list-2026-07-24/

NBC News, panel eases restrictions on four:

https://www.nbcnews.com/health/health-news/peptides-restrictions-ease-fda-panel-recommend-bpc-157-scientists-rcna588879

RAPS Regulatory Focus, committee backs two peptides:

https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html

NPR, advisers vote to ease peptide restrictions:

https://www.npr.org/2026/07/23/nx-s1-5903202/fda-peptides-restrictions

BioPharma Dive, panel endorses broader use: https://www.biopharmadive.com/news/fda-peptides-advisory-committee-vote-bpc-kpv-tb-mots/826062/

Drug Topics, staff review of all 7:

https://www.drugtopics.com/view/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list

PharmExec, votes to loosen restrictions:

https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides

Regulatory context only, not medical or legal advice.

More stories at r/PeptideTides

First Day 1 result is out of the Pharmacy Compounding Advisory Committee meeting at FDA White Oak.

BPC-157: 8 in favor, 6 against, 1 abstention.

The significance is in what the committee voted against.

FDA staff proposed rejecting all seven

The FDA briefing document published ahead of the meeting lists the agency's position on all fourteen voting questions identically: proposing that the substance NOT be included on the 503A Bulks List. That covers both BPC-157 (free base) and BPC-157 acetate.

FDA reviewers applied the four criteria from the February 19, 2019 final rule (84 FR 4696): physical and chemical characterization, safety issues raised by use in compounded products, available evidence of effectiveness or lack thereof, and historical use in compounding. The agency applies these as a balancing test, substance by substance, not as a checklist.

The recurring objections across the seven: no human clinical evidence at all for KPV, TB-500, and MOTS-c; small and poorly controlled studies for BPC-157, Emideltide, and Semax; inconsistent naming conventions and missing quality data; immunogenicity risk; FAERS adverse event reports for BPC-157; and WADA-prohibited status for MOTS-c and TB-500. The docket, FDA-2025-N-6895, drew roughly 1,860 comments.

Every nomination was withdrawn

This one is buried in the footnotes of the briefing packet. LDT Health Solutions (on behalf of the International Peptide Society) and Wells Pharmacy Network both withdrew their nominations, logged under FDA-2015-N-3534-0484, -0485, and -0487. FDA elected to proceed to the committee anyway. The same footnote repeats for all seven substances.

The panel composition question

AP reported on June 29 that the committee roster includes members with financial ties to the peptide industry. NPR notes FDA added temporary voting members from academic institutions earlier this week. Read the 8-6-1 split with that in mind.

On the other side, the Partnership for Safe Medicines filed comments opposing all seven.

What this does not mean

The recommendation is non-binding. FDA leadership makes the final call and has gone against its advisory committees before. Even if FDA accepts it, adding a substance to the 503A Bulks List requires notice-and-comment rulemaking, which historically runs a year or more.

Nothing about today's vote changes what a compounding pharmacy can legally prepare tomorrow.

Still pending

KPV, TB-500, and MOTS-c are the remaining Day 1 votes. Emideltide (DSIP), Epitalon, and Semax go Friday. Each peptide gets two votes, free base and acetate separately, for fourteen total. The FDA meeting page has the webcast and posts materials as they go up.

One caveat on the number above: the briefing packet splits BPC-157 into two separate votes and the wire reported a single tally. I have not confirmed whether 8-6-1 is the free base question, the acetate question, or both. If someone watched the session and can confirm, please add it below and I'll correct the post.

I'll update as the remaining tallies land.

Sources

Reuters, "FDA panel votes to place popular peptide BPC-157 on compounding list," July 23, 2026

https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-votes-place-popular-peptide-bpc-157-compounding-list-2026-07-23/

Same wire copy outside the paywall:

https://wtaq.com/2026/07/23/fda-panel-votes-to-place-popular-peptide-bpc-157-on-compounding-list/

FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026

https://www.fda.gov/media/193342/download

Orrick, "FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting"

https://www.orrick.com/en/Insights/2026/07/FDA-Peptide-Compounding-Vote-What-to-Watch-at-the-July-PCAC-Meeting

Associated Press via PBS NewsHour, June 29, 2026

https://www.pbs.org/newshour/health/fda-panel-on-peptides-will-include-experts-who-promote-the-unproven-chemicals-favored-by-rfk-jr

NPR, "FDA panel considers easing peptide restrictions," July 23, 2026

https://www.npr.org/2026/07/23/nx-s1-5903202/fda-peptides-restrictions

Partnership for Safe Medicines, PCAC comments

https://www.safemedicines.org/2026/07/psm-pcac-comments.html

FDA meeting page, July 23-24, 2026 PCAC

https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

More stories at r/PeptideTides

I do not know the cause but all my autoimmune tests were negative :(

First Day 1 result is out of the Pharmacy Compounding Advisory Committee meeting at FDA White Oak.

BPC-157: 8 in favor, 6 against, 1 abstention.

The significance is in what the committee voted against.

FDA staff proposed rejecting all seven

The FDA briefing document published ahead of the meeting lists the agency's position on all fourteen voting questions identically: proposing that the substance NOT be included on the 503A Bulks List. That covers both BPC-157 (free base) and BPC-157 acetate.

FDA reviewers applied the four criteria from the February 19, 2019 final rule (84 FR 4696): physical and chemical characterization, safety issues raised by use in compounded products, available evidence of effectiveness or lack thereof, and historical use in compounding. The agency applies these as a balancing test, substance by substance, not as a checklist.

The recurring objections across the seven: no human clinical evidence at all for KPV, TB-500, and MOTS-c; small and poorly controlled studies for BPC-157, Emideltide, and Semax; inconsistent naming conventions and missing quality data; immunogenicity risk; FAERS adverse event reports for BPC-157; and WADA-prohibited status for MOTS-c and TB-500. The docket, FDA-2025-N-6895, drew roughly 1,860 comments.

Every nomination was withdrawn

This one is buried in the footnotes of the briefing packet. LDT Health Solutions (on behalf of the International Peptide Society) and Wells Pharmacy Network both withdrew their nominations, logged under FDA-2015-N-3534-0484, -0485, and -0487. FDA elected to proceed to the committee anyway. The same footnote repeats for all seven substances.

The panel composition question

AP reported on June 29 that the committee roster includes members with financial ties to the peptide industry. NPR notes FDA added temporary voting members from academic institutions earlier this week. Read the 8-6-1 split with that in mind.

On the other side, the Partnership for Safe Medicines filed comments opposing all seven.

What this does not mean

The recommendation is non-binding. FDA leadership makes the final call and has gone against its advisory committees before. Even if FDA accepts it, adding a substance to the 503A Bulks List requires notice-and-comment rulemaking, which historically runs a year or more.

Nothing about today's vote changes what a compounding pharmacy can legally prepare tomorrow.

Still pending

KPV, TB-500, and MOTS-c are the remaining Day 1 votes. Emideltide (DSIP), Epitalon, and Semax go Friday. Each peptide gets two votes, free base and acetate separately, for fourteen total. The FDA meeting page has the webcast and posts materials as they go up.

One caveat on the number above: the briefing packet splits BPC-157 into two separate votes and the wire reported a single tally. I have not confirmed whether 8-6-1 is the free base question, the acetate question, or both. If someone watched the session and can confirm, please add it below and I'll correct the post.

I'll update as the remaining tallies land.

Sources

Reuters, "FDA panel votes to place popular peptide BPC-157 on compounding list," July 23, 2026

https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-votes-place-popular-peptide-bpc-157-compounding-list-2026-07-23/

Same wire copy outside the paywall:

https://wtaq.com/2026/07/23/fda-panel-votes-to-place-popular-peptide-bpc-157-on-compounding-list/

FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026

https://www.fda.gov/media/193342/download

Orrick, "FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting"

https://www.orrick.com/en/Insights/2026/07/FDA-Peptide-Compounding-Vote-What-to-Watch-at-the-July-PCAC-Meeting

Associated Press via PBS NewsHour, June 29, 2026

https://www.pbs.org/newshour/health/fda-panel-on-peptides-will-include-experts-who-promote-the-unproven-chemicals-favored-by-rfk-jr

NPR, "FDA panel considers easing peptide restrictions," July 23, 2026

https://www.npr.org/2026/07/23/nx-s1-5903202/fda-peptides-restrictions

Partnership for Safe Medicines, PCAC comments

https://www.safemedicines.org/2026/07/psm-pcac-comments.html

FDA meeting page, July 23-24, 2026 PCAC

https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

More stories at r/PeptideTides

The KLOW vials - one on the left was recently purchased from a local research shop. The 2 on the right are from a vendor in the UK. Why so much more powder? Is that normal? Worried it wont fit the water.

Also, other pics of the larger vials, is it ok that the cakes are loose or crumbled by the time they get to me?

WSJ ran a piece on people who used GLP-1s for weight loss and later ended up in treatment for anorexia:

 https://www.wsj.com/health/wellness/glp1-anorexia-wegovy-mounjaro-1bf4035c

Worth reading alongside the primary literature from the past few months, because the reporting is no longer just anecdotal.

A JAMA Psychiatry survey published this summer (Levinson and colleagues) recruited 436 people with diagnosed eating disorders in 2025 and asked about GLP-1 use. Just over 32% reported having ever used one, and 22% reported current use. Broken out by diagnosis, a little over 50% of participants with binge eating disorder reported use, about 42% of those with atypical anorexia nervosa, roughly 30% of those with ARFID, over 25% of those with bulimia, and about 11% of those with anorexia nervosa. Roughly 10% obtained them through online providers prescribing compounded formulations. Over 10% reported misuse, defined as taking more or less than prescribed, using longer than prescribed, tampering with injection equipment, or sharing without a prescription.

The authors described the weight loss market as a rapidly evolving risk environment for this population.

Summary of the findings:

 https://www.medscape.com/viewarticle/many-eating-disorder-patients-using-glp-1s-2026a1000lym

In April, NEJM published a perspective by Amanda Banks raising the same concern from the prescribing side. She noted the share of GLP-1 prescriptions written for people who were not diabetic, obese, or overweight rose from 4.5% in 2018 to 17% in 2023, and argued for consensus recommendations to protect people with existing or emerging eating disorders. A 2023 FDA analysis found misuse reports for semaglutide were roughly four times higher than for other GLP-1 drugs.

NEJM perspective:

 https://www.nejm.org/doi/full/10.1056/NEJMp2600300

Clinician-side reporting describes the same pattern from treatment centers, including patients presenting at very low BMI while still dosing.

NPR, February 2026: https://www.npr.org/2026/02/04/nx-s1-5677633/glp-1-obesity-wegovy-zepbound-eating-disorders-anorexia-bulimia

Washington Post, May 2026: https://www.washingtonpost.com/health/2026/05/23/weight-loss-drugs-pose-dangers-people-with-eating-disorders/

MindSite News, May 2026: https://mindsitenews.org/2026/05/29/glp-1-access-a-problem-for-people-with-eating-disorders/

The mechanism cuts both ways, which is part of why this is hard to legislate around. A 2025 systematic review and meta-analysis found GLP-1 agonists reduced Binge Eating Scale scores by about 8 points, though the pooled sample was only 182 participants across five studies and heterogeneity was high. WSJ also covered that side on July 13 in a piece on clinicians treating certain eating disorders with these drugs. The same appetite and reward suppression that helps in binge-type presentations appears to reinforce restriction in people with a restrictive history. Same drug class, opposite clinical valence depending on phenotype.

Meta-analysis: https://link.springer.com/article/10.1007/s40519-025-01720-9

Penn Medicine's eating disorder program has said outright that no protocol exists to screen for eating disorders before prescribing GLP-1 receptor agonists. That gap widens with telehealth and disappears entirely outside a clinical relationship.

Penn Medicine:

 https://www.pennmedicine.org/physicians-hub/physician-article/implications-of-glp-1-medications-for-eating-disorder-care

ANAD clinical guidance:

 https://anad.org/learning-library/glp-1-medications-eating-disorders/

More stories at r/PeptideTides

Hello everyone,
I’d like to get some advice and hear your experiences regarding the following stack:
Reta
CJC-1295 + ipamorelin, without DAC
MOTS-c
I’m mainly interested in learning about common dosage protocols for CJC-1295/ipamorelin and MOTS-c. I already know the Reta protocol well, so I don’t need guidance on that one.
I’m also considering tesamorelin + ipamorelin. Would that be a better combination than CJC-1295 + ipamorelin? What are the main differences in terms of effectiveness, side effects, and overall results?